Details of the Drug

General Information of Drug (ID: DMC0GSJ)

Drug Name
Efavirenz
Synonyms
EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 315.67
Topological Polar Surface Area (xlogp) 4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
0.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 40 - 55 hours [3]
Metabolism
The drug is metabolized via the cytochrome P450 system [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 27.15214 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.005 mg/mL [2]
Chemical Identifiers
Formula
C14H9ClF3NO2
IUPAC Name
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
Canonical SMILES
C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
InChI
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
InChIKey
XPOQHMRABVBWPR-ZDUSSCGKSA-N
Cross-matching ID
PubChem CID
64139
ChEBI ID
CHEBI:119486
CAS Number
154598-52-4
DrugBank ID
DB00625
TTD ID
D07HVY
VARIDT ID
DR00412
INTEDE ID
DR0560
ACDINA ID
D00222

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Efavirenz
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Major Increased metabolism of Efavirenz caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Delavirdine DM3NF5G Moderate Decreased metabolism of Efavirenz caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Efavirenz caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [66]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Efavirenz caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [66]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [66]
Dolutegravir DMCZGRE Major Increased metabolism of Efavirenz caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Elvitegravir DMG9B1U Moderate Increased metabolism of Efavirenz caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Etravirine DMGV8QU Major Increased metabolism of Efavirenz caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [66]
Didanosine DMI2QPE Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [66]
Lopinavir DMITQS0 Major Increased metabolism of Efavirenz caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Efavirenz and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [71]
Amprenavir DMLMXE0 Moderate Increased metabolism of Efavirenz caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [66]
Darunavir DMN3GCH Moderate Increased metabolism of Efavirenz caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Atazanavir DMSYRBX Moderate Increased metabolism of Efavirenz caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Maraviroc DMTL94F Major Increased metabolism of Efavirenz caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
⏷ Show the Full List of 19 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Efavirenz (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [67]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Tretinoin. Acne vulgaris [ED80] [70]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Isotretinoin. Acne vulgaris [ED80] [70]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [66]
Repaglinide DM5SXUV Moderate Increased metabolism of Efavirenz caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [73]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Pioglitazone. Acute diabete complication [5A2Y] [66]
Nateglinide DMLK2QH Moderate Decreased metabolism of Efavirenz caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [74]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Efavirenz and Ivosidenib. Acute myeloid leukaemia [2A60] [71]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Tagraxofusp. Acute myeloid leukaemia [2A60] [66]
Midostaurin DMI6E0R Moderate Increased metabolism of Efavirenz caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [75]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Efavirenz and Idarubicin. Acute myeloid leukaemia [2A60] [71]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Efavirenz and Daunorubicin. Acute myeloid leukaemia [2A60] [71]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Efavirenz and Gilteritinib. Acute myeloid leukaemia [2A60] [71]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Efavirenz and Oliceridine. Acute pain [MG31] [71]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Rivastigmine. Alzheimer disease [8A20] [70]
Donepezil DMIYG7Z Moderate Increased metabolism of Efavirenz caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [71]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Efavirenz and Metronidazole. Amoebiasis [1A36] [67]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Inotersen. Amyloidosis [5D00] [66]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ivabradine. Angina pectoris [BA40] [76]
Bepridil DM0RKS4 Major Decreased metabolism of Efavirenz caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [71]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Efavirenz and Dronedarone. Angina pectoris [BA40] [70]
Nifedipine DMSVOZT Moderate Increased metabolism of Efavirenz caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [71]
Bedaquiline DM3906J Major Increased metabolism of Efavirenz caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [76]
Clorazepate DMC3JST Moderate Increased metabolism of Efavirenz caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [71]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Efavirenz caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [77]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Oxymetholone. Aplastic anaemia [3A70] [66]
Cilostazol DMZMSCT Moderate Increased metabolism of Efavirenz caused by Cilostazol mediated induction of CYP450 enzyme. Arterial occlusive disease [BD40] [71]
Posaconazole DMUL5EW Moderate Increased metabolism of Efavirenz caused by Posaconazole mediated induction of UGT. Aspergillosis [1F20] [78]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Levalbuterol. Asthma [CA23] [79]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Terbutaline. Asthma [CA23] [80]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Pirbuterol. Asthma [CA23] [80]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Salbutamol. Asthma [CA23] [81]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Formoterol. Asthma [CA23] [80]
Zileuton DMVRIC2 Moderate Increased metabolism of Efavirenz caused by Zileuton mediated induction of CYP450 enzyme. Asthma [CA23] [71]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Efavirenz and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [71]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Efavirenz and Desipramine. Attention deficit hyperactivity disorder [6A05] [71]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Efavirenz and Ofloxacin. Bacterial infection [1A00-1C4Z] [71]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Clavulanate. Bacterial infection [1A00-1C4Z] [66]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Efavirenz caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Clarithromycin DM4M1SG Moderate Increased metabolism of Efavirenz caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Trovafloxacin DM6AN32 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Trovafloxacin. Bacterial infection [1A00-1C4Z] [66]
Sulfamethoxazole DMB08GE Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [66]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Efavirenz and Sparfloxacin. Bacterial infection [1A00-1C4Z] [83]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Efavirenz and Gemifloxacin. Bacterial infection [1A00-1C4Z] [71]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Efavirenz and Norfloxacin. Bacterial infection [1A00-1C4Z] [71]
Rabeprazole DMMZXIW Moderate Increased metabolism of Efavirenz caused by Rabeprazole mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [71]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Efavirenz and Levofloxacin. Bacterial infection [1A00-1C4Z] [71]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Minocycline. Bacterial infection [1A00-1C4Z] [66]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Efavirenz and Lomefloxacin. Bacterial infection [1A00-1C4Z] [71]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Efavirenz and Telithromycin. Bacterial infection [1A00-1C4Z] [71]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Efavirenz and Retigabine. Behcet disease [4A62] [71]
Cariprazine DMJYDVK Moderate Increased metabolism of Efavirenz caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [84]
Erdafitinib DMI782S Major Increased metabolism of Efavirenz caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [85]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Efavirenz and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [86]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Efavirenz and Loperamide. Bowel habit change [ME05] [87]
Temozolomide DMKECZD Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Temozolomide. Brain cancer [2A00] [66]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Lomustine. Brain cancer [2A00] [66]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Efavirenz and Eribulin. Breast cancer [2C60-2C6Y] [71]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Efavirenz caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [88]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Efavirenz and Lapatinib. Breast cancer [2C60-2C6Y] [71]
HKI-272 DM6QOVN Major Increased metabolism of Efavirenz caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [67]
LY2835219 DM93VBZ Moderate Increased metabolism of Efavirenz caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [89]
Exemestane DM9HPW3 Moderate Increased metabolism of Efavirenz caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Efavirenz caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [91]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Pralatrexate. Breast cancer [2C60-2C6Y] [66]
Tucatinib DMBESUA Moderate Increased metabolism of Efavirenz caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [92]
Palbociclib DMD7L94 Moderate Increased metabolism of Efavirenz caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [67]
Alpelisib DMEXMYK Moderate Increased metabolism of Efavirenz caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [76]
Letrozole DMH07Y3 Moderate Increased metabolism of Efavirenz caused by Letrozole mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [71]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Efavirenz caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [91]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Efavirenz and Tamoxifen. Breast cancer [2C60-2C6Y] [71]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Efavirenz caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [93]
Bosutinib DMTI8YE Major Increased metabolism of Efavirenz caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [94]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [66]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Fluoxymesterone. Breast cancer [2C60-2C6Y] [66]
Estradiol DMUNTE3 Moderate Increased metabolism of Efavirenz caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [91]
Atorvastatin DMF28YC Moderate Increased metabolism of Efavirenz caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [95]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [66]
Macitentan DMP79A1 Moderate Increased metabolism of Efavirenz caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [96]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Chenodiol. Cholelithiasis [DC11] [66]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Efavirenz and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [97]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Efavirenz and Olodaterol. Chronic obstructive pulmonary disease [CA22] [80]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Vilanterol. Chronic obstructive pulmonary disease [CA22] [79]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Efavirenz and Salmeterol. Chronic obstructive pulmonary disease [CA22] [80]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Indacaterol. Chronic obstructive pulmonary disease [CA22] [80]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Arformoterol. Chronic obstructive pulmonary disease [CA22] [80]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Efavirenz caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [77]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Efavirenz caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [98]
Ketoprofen DMRKXPT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Ketoprofen. Chronic pain [MG30] [66]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Regorafenib. Colorectal cancer [2B91] [66]
Irinotecan DMP6SC2 Moderate Increased metabolism of Efavirenz caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [99]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Intedanib. Colorectal cancer [2B91] [66]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Efavirenz and Isoproterenol. Conduction disorder [BC63] [80]
Drospirenone DM1A9W3 Moderate Increased metabolism of Efavirenz caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [76]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Efavirenz caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [76]
Ulipristal DMBNI20 Moderate Increased metabolism of Efavirenz caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [76]
Levobupivacaine DM783CH Minor Increased metabolism of Efavirenz caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [100]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Efavirenz and Halothane. Corneal disease [9A76-9A78] [71]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Efavirenz and Propofol. Corneal disease [9A76-9A78] [101]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Efavirenz and Sevoflurane. Corneal disease [9A76-9A78] [71]
Alfentanil DMVO0UB Moderate Increased metabolism of Efavirenz caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [102]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Efavirenz and Probucol. Coronary atherosclerosis [BA80] [71]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Efavirenz and Clofazimine. Crohn disease [DD70] [71]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Efavirenz and Mifepristone. Cushing syndrome [5A70] [70]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Efavirenz and Pasireotide. Cushing syndrome [5A70] [71]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Efavirenz and Osilodrostat. Cushing syndrome [5A70] [71]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Efavirenz caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [103]
Ivacaftor DMZC1HS Moderate Increased metabolism of Efavirenz caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [104]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Ethanol. Cystitis [GC00] [66]
MK-8228 DMOB58Q Moderate Accelerated clearance of Efavirenz due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [67]
Rivaroxaban DMQMBZ1 Moderate Accelerated clearance of Efavirenz due to the transporter induction by Rivaroxaban. Deep vein thrombosis [BD71] [105]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Efavirenz and Sertraline. Depression [6A70-6A7Z] [71]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Efavirenz and Trimipramine. Depression [6A70-6A7Z] [71]
Vilazodone DM4LECQ Moderate Increased metabolism of Efavirenz caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [106]
Nefazodone DM4ZS8M Moderate Increased metabolism of Efavirenz caused by Nefazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [71]
Vortioxetine DM6F1PU Moderate Increased metabolism of Efavirenz caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [107]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Milnacipran. Depression [6A70-6A7Z] [66]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Efavirenz and Escitalopram. Depression [6A70-6A7Z] [70]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Efavirenz and Clomipramine. Depression [6A70-6A7Z] [71]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Efavirenz and Trazodone. Depression [6A70-6A7Z] [71]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Efavirenz and Doxepin. Depression [6A70-6A7Z] [71]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Efavirenz and Maprotiline. Depression [6A70-6A7Z] [71]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [66]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Efavirenz caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [108]
Oxybutynine DMJPBAX Moderate Increased metabolism of Efavirenz caused by Oxybutynine mediated induction of CYP450 enzyme. Discovery agent [N.A.] [71]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Efavirenz and Deutetrabenazine. Dystonic disorder [8A02] [71]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Efavirenz and Ingrezza. Dystonic disorder [8A02] [71]
Diazepam DM08E9O Moderate Increased metabolism of Efavirenz caused by Diazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Zonisamide DM0DTF7 Moderate Increased metabolism of Efavirenz caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [109]
Primidone DM0WX6I Moderate Increased metabolism of Efavirenz caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [110]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Felbamate. Epilepsy/seizure [8A61-8A6Z] [66]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Efavirenz caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [77]
Cenobamate DMGOVHA Moderate Increased metabolism of Efavirenz caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [111]
Tiagabine DMKSQG0 Moderate Increased metabolism of Efavirenz caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Stiripentol DMMSDOY Moderate Increased metabolism of Efavirenz caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [76]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Efavirenz caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [110]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Efavirenz caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [76]
Clonazepam DMTO13J Moderate Increased metabolism of Efavirenz caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Rufinamide DMWE60C Moderate Increased metabolism of Efavirenz caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [77]
Ethotoin DMXWOCP Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [66]
Phenobarbital DMXZOCG Moderate Increased metabolism of Efavirenz caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [110]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Cannabidiol. Epileptic encephalopathy [8A62] [76]
Mefenamic acid DMK7HFI Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Mefenamic acid. Female pelvic pain [GA34] [66]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Dantrolene. Fever [MG26] [66]
Praziquantel DMOU1PK Moderate Increased metabolism of Efavirenz caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [112]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Efavirenz caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [113]
Tazemetostat DMWP1BH Major Increased metabolism of Efavirenz caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [114]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Efavirenz and Solifenacin. Functional bladder disorder [GC50] [71]
Mirabegron DMS1GYT Minor Increased metabolism of Efavirenz caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [115]
Tolterodine DMSHPW8 Moderate Increased metabolism of Efavirenz caused by Tolterodine mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [71]
Itraconazole DMCR1MV Moderate Increased metabolism of Efavirenz caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [67]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Efavirenz and Pentamidine. Fungal infection [1F29-1F2F] [71]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Terbinafine. Fungal infection [1F29-1F2F] [66]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Efavirenz and Ketoconazole. Fungal infection [1F29-1F2F] [71]
Atovaquone DMY4UMW Major Increased metabolism of Efavirenz caused by Atovaquone mediated induction of UGT. Fungal infection [1F29-1F2F] [71]
Ripretinib DM958QB Moderate Increased metabolism of Efavirenz caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [67]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Efavirenz and Sunitinib. Gastrointestinal stromal tumour [2B5B] [71]
Avapritinib DMK2GZX Major Increased metabolism of Efavirenz caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [76]
Colchicine DM2POTE Moderate Increased metabolism of Efavirenz caused by Colchicine mediated induction of CYP450 enzyme. Gout [FA25] [71]
Ergotamine DMKR3C5 Major Decreased metabolism of Efavirenz caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [71]
Boceprevir DMBSHMF Moderate Increased metabolism of Efavirenz caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [116]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Lamivudine. Hepatitis virus infection [1E50-1E51] [66]
Simeprevir DMLUA9D Major Increased metabolism of Efavirenz caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [117]
Telaprevir DMMRV29 Moderate Increased metabolism of Efavirenz caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [118]
Daclatasvir DMSFK9V Major Increased metabolism of Efavirenz caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [76]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [66]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [66]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [119]
Rifapentine DMCHV4I Moderate Increased metabolism of Efavirenz caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [77]
Pretomanid DMDYA31 Major Increased metabolism of Efavirenz caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [120]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Brentuximab vedotin. Hodgkin lymphoma [2B30] [66]
Simvastatin DM30SGU Moderate Increased metabolism of Efavirenz caused by Simvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [95]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Fluvastatin. Hyper-lipoproteinaemia [5C80] [66]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Fenofibrate. Hyper-lipoproteinaemia [5C80] [66]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Efavirenz and Mipomersen. Hyper-lipoproteinaemia [5C80] [121]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [66]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Efavirenz and Teriflunomide. Hyper-lipoproteinaemia [5C80] [70]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Efavirenz and BMS-201038. Hyper-lipoproteinaemia [5C80] [122]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Moexipril. Hypertension [BA00-BA04] [66]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Captopril. Hypertension [BA00-BA04] [66]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Methyldopa. Hypertension [BA00-BA04] [66]
Losartan DM72JXH Moderate Increased metabolism of Efavirenz caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Levamlodipine DM92S6N Moderate Increased metabolism of Efavirenz caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Verapamil DMA7PEW Moderate Increased metabolism of Efavirenz caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Perindopril. Hypertension [BA00-BA04] [66]
Felodipine DMOSW35 Moderate Increased metabolism of Efavirenz caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [71]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Quinapril. Hypertension [BA00-BA04] [66]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Lisinopril. Hypertension [BA00-BA04] [66]
Conivaptan DM1V329 Moderate Decreased metabolism of Efavirenz caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [123]
Tolvaptan DMIWFRL Moderate Increased metabolism of Efavirenz caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [76]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Efavirenz caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [71]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [66]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Vitamin B3. Inborn lipid metabolism error [5C52] [66]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [66]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [66]
Lesinurad DMUR64T Moderate Decreased metabolism of Efavirenz caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [124]
Meclofenamic acid DM05FXR Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [66]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Efavirenz caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [125]
Suvorexant DM0E6S3 Moderate Increased metabolism of Efavirenz caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [126]
Amobarbital DM0GQ8N Moderate Increased metabolism of Efavirenz caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [77]
Ramelteon DM7IW9J Moderate Increased metabolism of Efavirenz caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [127]
Triazolam DMETYK5 Major Increased plasma concentrations of Efavirenz and Triazolam due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [71]
Zaleplon DMGFWSM Minor Increased metabolism of Efavirenz caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [128]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Efavirenz caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [129]
ITI-007 DMUQ1DO Major Increased metabolism of Efavirenz caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [130]
Quazepam DMY4D87 Moderate Increased metabolism of Efavirenz caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
Estazolam DMZGXUM Moderate Increased metabolism of Efavirenz caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Polyethylene glycol. Irritable bowel syndrome [DD91] [70]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Efavirenz and Phenolphthalein. Irritable bowel syndrome [DD91] [70]
Naloxegol DML0B41 Moderate Increased metabolism of Efavirenz caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [131]
Pemigatinib DM819JF Major Increased metabolism of Efavirenz caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [76]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Efavirenz and Crizotinib. Lung cancer [2C25] [71]
Brigatinib DM7W94S Major Increased metabolism of Efavirenz caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [67]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Efavirenz and Porfimer Sodium. Lung cancer [2C25] [132]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Efavirenz and Ceritinib. Lung cancer [2C25] [71]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Efavirenz caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [133]
PF-06463922 DMKM7EW Major Increased metabolism of Efavirenz caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [134]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Alectinib. Lung cancer [2C25] [66]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Efavirenz and Osimertinib. Lung cancer [2C25] [71]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and BIBW 2992. Lung cancer [2C25] [66]
Pralsetinib DMWU0I2 Moderate Increased metabolism of Efavirenz caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [135]
Capmatinib DMYCXKL Major Increased metabolism of Efavirenz caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [136]
Selpercatinib DMZR15V Major Increased metabolism of Efavirenz caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Artemether DM48QOT Major Increased metabolism of Efavirenz caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [67]
Proguanil DMBL79I Major Increased metabolism of Efavirenz caused by Proguanil mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [71]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Efavirenz and Halofantrine. Malaria [1F40-1F45] [137]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Efavirenz and Hydroxychloroquine. Malaria [1F40-1F45] [71]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Sulphadoxine. Malaria [1F40-1F45] [66]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Efavirenz and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [71]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [66]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Idelalisib. Mature B-cell leukaemia [2A82] [138]
GDC-0199 DMH0QKA Major Increased metabolism of Efavirenz caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [139]
IPI-145 DMWA24P Moderate Increased metabolism of Efavirenz caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [140]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Efavirenz and Arsenic trioxide. Mature B-cell lymphoma [2A85] [71]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Efavirenz caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [141]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Clofarabine. Mature B-cell lymphoma [2A85] [142]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Blinatumomab. Mature B-cell lymphoma [2A85] [66]
Ibrutinib DMHZCPO Moderate Increased metabolism of Efavirenz caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [143]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Mercaptopurine. Mature B-cell lymphoma [2A85] [66]
Ponatinib DMYGJQO Moderate Increased metabolism of Efavirenz caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [67]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Cytarabine. Mature B-cell lymphoma [2A85] [66]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Arry-162. Melanoma [2C30] [66]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Efavirenz and Vemurafenib. Melanoma [2C30] [71]
Selumetinib DMC7W6R Major Increased metabolism of Efavirenz caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [144]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Ipilimumab. Melanoma [2C30] [66]
Dacarbazine DMNPZL4 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Dacarbazine. Melanoma [2C30] [66]
LGX818 DMNQXV8 Major Increased metabolism of Efavirenz caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [145]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Efavirenz caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [76]
Estrone DM5T6US Moderate Increased metabolism of Efavirenz caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [91]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Efavirenz caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [146]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Danazol. Menstrual cycle bleeding disorder [GA20] [66]
Ubrogepant DM749I3 Moderate Increased metabolism of Efavirenz caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [147]
Almogran DM7I64Z Moderate Increased metabolism of Efavirenz caused by Almogran mediated induction of CYP450 enzyme. Migraine [8A80] [71]
Rimegepant DMHOAUG Major Increased metabolism of Efavirenz caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [148]
Exjade DMHPRWG Moderate Decreased metabolism of Efavirenz caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [149]
Flibanserin DM70DTN Moderate Increased metabolism of Efavirenz caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [150]
Midazolam DMXOELT Major Increased plasma concentrations of Efavirenz and Midazolam due to competitive inhibition of the same metabolic pathway. Mood/affect symptom [MB24] [71]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Riluzole. Motor neuron disease [8B60] [66]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Carfilzomib. Multiple myeloma [2A83] [66]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Efavirenz and Panobinostat. Multiple myeloma [2A83] [71]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Efavirenz and Thalidomide. Multiple myeloma [2A83] [151]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Elotuzumab. Multiple myeloma [2A83] [66]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Tecfidera. Multiple sclerosis [8A40] [66]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Siponimod. Multiple sclerosis [8A40] [67]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Fingolimod. Multiple sclerosis [8A40] [70]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ozanimod. Multiple sclerosis [8A40] [152]
Deflazacort DMV0RNS Major Increased metabolism of Efavirenz caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [76]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Efavirenz and Romidepsin. Mycosis fungoides [2B01] [71]
Fedratinib DM4ZBK6 Major Increased metabolism of Efavirenz caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [76]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Efavirenz and Nilotinib. Myeloproliferative neoplasm [2A20] [71]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Efavirenz caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [153]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Efavirenz and Dasatinib. Myeloproliferative neoplasm [2A20] [71]
Prasugrel DM7MT6E Minor Decreased metabolism of Efavirenz caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [76]
Modafinil DMYILBE Moderate Increased metabolism of Efavirenz caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [71]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Efavirenz and Promethazine. Nausea/vomiting [MD90] [71]
Rolapitant DM8XP26 Moderate Increased metabolism of Efavirenz caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [76]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Efavirenz and Granisetron. Nausea/vomiting [MD90] [71]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Efavirenz and Dolasetron. Nausea/vomiting [MD90] [71]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Efavirenz and Ondansetron. Nausea/vomiting [MD90] [71]
E-2007 DMJDYNQ Moderate Increased metabolism of Efavirenz caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [76]
Bupropion DM5PCS7 Moderate Increased metabolism of Efavirenz caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [67]
Entrectinib DMMPTLH Major Increased metabolism of Efavirenz caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [154]
Orlistat DMRJSP8 Moderate Altered absorption of Efavirenz caused by Orlistat. Obesity [5B80-5B81] [155]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Efavirenz and Levomethadyl Acetate. Opioid use disorder [6C43] [76]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Efavirenz and Lofexidine. Opioid use disorder [6C43] [71]
S-297995 DM26IH8 Moderate Increased metabolism of Efavirenz caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [76]
Naproxen DMZ5RGV Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Naproxen. Osteoarthritis [FA00-FA05] [66]
Olaparib DM8QB1D Major Increased metabolism of Efavirenz caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [67]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Efavirenz and Rucaparib. Ovarian cancer [2C73] [71]
Etodolac DM6WJO9 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Etodolac. Pain [MG30-MG3Z] [66]
Ibuprofen DM8VCBE Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Ibuprofen. Pain [MG30-MG3Z] [66]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Efavirenz and Triclabendazole. Parasitic worm infestation [1F90] [71]
Istradefylline DM20VSK Moderate Increased metabolism of Efavirenz caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [156]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Efavirenz and Pimavanserin. Parkinsonism [8A00] [71]
Bromocriptine DMVE3TK Moderate Increased metabolism of Efavirenz caused by Bromocriptine mediated induction of CYP450 enzyme. Parkinsonism [8A00] [71]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Efavirenz and Apomorphine. Parkinsonism [8A00] [71]
Abametapir DM2RX0I Moderate Decreased metabolism of Efavirenz caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [157]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Efavirenz and Famotidine. Peptic ulcer [DA61] [67]
Macimorelin DMQYJIR Moderate Increased metabolism of Efavirenz caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [158]
Lefamulin DME6G97 Major Increased metabolism of Efavirenz caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [159]
Prednisone DM2HG4X Moderate Increased metabolism of Efavirenz caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [71]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Efavirenz caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [71]
Bromfenac DMKB79O Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Bromfenac. Postoperative inflammation [1A00-CA43] [66]
Ergonovine DM0VEC1 Major Decreased metabolism of Efavirenz caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [160]
Lonafarnib DMGM2Z6 Major Increased metabolism of Efavirenz caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [161]
Ritodrine DM4V6RL Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Ritodrine. Preterm labour/delivery [JB00] [80]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Efavirenz and Degarelix. Prostate cancer [2C82] [71]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and ABIRATERONE. Prostate cancer [2C82] [66]
Nilutamide DMFN07X Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Nilutamide. Prostate cancer [2C82] [66]
Enzalutamide DMGL19D Moderate Increased metabolism of Efavirenz caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [162]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Efavirenz and Relugolix. Prostate cancer [2C82] [71]
Darolutamide DMV7YFT Moderate Increased metabolism of Efavirenz caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [163]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Bicalutamide. Prostate cancer [2C82] [66]
Silodosin DMJSBT6 Moderate Increased metabolism of Efavirenz caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [67]
Dutasteride DMQ4TJK Moderate Increased metabolism of Efavirenz caused by Dutasteride mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [71]
Apremilast DMTWS9E Moderate Increased metabolism of Efavirenz caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [164]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Efavirenz and Levomepromazine. Psychotic disorder [6A20-6A25] [71]
Ambrisentan DMD1QXW Moderate Increased metabolism of Efavirenz caused by Ambrisentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [71]
Riociguat DMXBLMP Moderate Increased metabolism of Efavirenz caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [165]
Everolimus DM8X2EH Moderate Accelerated clearance of Efavirenz due to the transporter induction by Everolimus. Renal cell carcinoma [2C90] [67]
Axitinib DMGVH6N Major Increased metabolism of Efavirenz caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [166]
Temsirolimus DMS104F Moderate Increased metabolism of Efavirenz caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [67]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Efavirenz and Gatifloxacin. Respiratory infection [CA07-CA4Z] [167]
Meloxicam DM2AR7L Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Meloxicam. Rheumatoid arthritis [FA20] [66]
Upadacitinib DM32B5U Moderate Increased metabolism of Efavirenz caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [168]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Tocilizumab. Rheumatoid arthritis [FA20] [66]
Oxaprozin DM9UB0P Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Oxaprozin. Rheumatoid arthritis [FA20] [66]
Tofacitinib DMBS370 Moderate Increased metabolism of Efavirenz caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [67]
Flurbiprofen DMGN4BY Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Flurbiprofen. Rheumatoid arthritis [FA20] [66]
Sulfasalazine DMICA9H Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Sulfasalazine. Rheumatoid arthritis [FA20] [66]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Sarilumab. Rheumatoid arthritis [FA20] [66]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Efavirenz and Leflunomide. Rheumatoid arthritis [FA20] [70]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Efavirenz and Quetiapine. Schizophrenia [6A20] [71]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Efavirenz and Mesoridazine. Schizophrenia [6A20] [70]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Efavirenz and Thioridazine. Schizophrenia [6A20] [70]
Aripiprazole DM3NUMH Moderate Increased metabolism of Efavirenz caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [169]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Efavirenz and Iloperidone. Schizophrenia [6A20] [71]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Efavirenz and Paliperidone. Schizophrenia [6A20] [71]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Efavirenz and Perphenazine. Schizophrenia [6A20] [71]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Efavirenz and Trifluoperazine. Schizophrenia [6A20] [71]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Efavirenz and Risperidone. Schizophrenia [6A20] [71]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Efavirenz and Amisulpride. Schizophrenia [6A20] [71]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Efavirenz and Asenapine. Schizophrenia [6A20] [71]
Pimozide DMW83TP Major Decreased metabolism of Efavirenz caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [170]
Fentanyl DM8WAHT Major Increased metabolism of Efavirenz caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [70]
Avanafil DM75CXN Moderate Increased metabolism of Efavirenz caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [171]
Tadalafil DMJZHT1 Moderate Increased metabolism of Efavirenz caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [76]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Efavirenz and Vardenafil. Sexual dysfunction [HA00-HA01] [71]
Voxelotor DMCS6M5 Major Increased metabolism of Efavirenz caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [172]
LDE225 DMM9F25 Major Increased metabolism of Efavirenz caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [173]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Efavirenz caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [76]
Larotrectinib DM26CQR Moderate Accelerated clearance of Efavirenz due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [67]
Methylprednisolone DM4BDON Moderate Increased metabolism of Efavirenz caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and PDX-101. Solid tumour/cancer [2A00-2F9Z] [66]
Docetaxel DMDI269 Moderate Increased metabolism of Efavirenz caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [174]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [76]
Armodafinil DMGB035 Moderate Increased metabolism of Efavirenz caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Efavirenz and LEE011. Solid tumour/cancer [2A00-2F9Z] [71]
Etoposide DMNH3PG Moderate Increased metabolism of Efavirenz caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Efavirenz caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Efavirenz and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [70]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Efavirenz and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [71]
Norethindrone DMTY169 Moderate Increased metabolism of Efavirenz caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [146]
Taxol DMUOT9V Moderate Increased metabolism of Efavirenz caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [175]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Efavirenz and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [71]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [66]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Efavirenz and Pitolisant. Somnolence [MG42] [71]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Efavirenz and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [71]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Disulfiram. Substance abuse [6C40] [66]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Naltrexone. Substance abuse [6C40] [176]
Warfarin DMJYCVW Moderate Decreased metabolism of Efavirenz caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [71]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Efavirenz and Adenosine. Supraventricular tachyarrhythmia [BC81] [177]
Fostamatinib DM6AUHV Moderate Increased metabolism of Efavirenz caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [178]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Eltrombopag. Thrombocytopenia [3B64] [66]
Apixaban DM89JLN Moderate Increased metabolism of Efavirenz caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [179]
Brilinta DMBR01X Moderate Increased metabolism of Efavirenz caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [70]
Clopidogrel DMOL54H Moderate Decreased metabolism of Efavirenz caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [180]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Efavirenz and Lenvatinib. Thyroid cancer [2D10] [71]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Efavirenz and Cabozantinib. Thyroid cancer [2D10] [71]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Methimazole. Thyrotoxicosis [5A02] [66]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Efavirenz and Tizanidine. Tonus and reflex abnormality [MB47] [71]
Trimetrexate DMDEA85 Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Trimetrexate. Toxoplasmosis [1F57] [66]
Sirolimus DMGW1ID Moderate Increased metabolism of Efavirenz caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [67]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Efavirenz and Tacrolimus. Transplant rejection [NE84] [71]
Saxagliptin DMGXENV Moderate Increased metabolism of Efavirenz caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [181]
Linagliptin DMWFJTR Moderate Increased metabolism of Efavirenz caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [182]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Efavirenz and Nitrofurantoin. Urinary tract infection [GC08] [66]
Elagolix DMB2C0E Moderate Increased metabolism of Efavirenz caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [183]
Astemizole DM2HN6Q Major Decreased metabolism of Efavirenz caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [71]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Efavirenz and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [184]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Efavirenz and Procainamide. Ventricular tachyarrhythmia [BC71] [70]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Efavirenz and Propafenone. Ventricular tachyarrhythmia [BC71] [71]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Efavirenz and Flecainide. Ventricular tachyarrhythmia [BC71] [71]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Efavirenz and Amiodarone. Ventricular tachyarrhythmia [BC71] [70]
⏷ Show the Full List of 394 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Efavirenz 200 mg capsule 200 mg Oral Capsule Oral
Efavirenz 50 mg capsule 50 mg Oral Capsule Oral
Efavirenz 100 mg capsule 100 mg Oral Capsule Oral
Efavirenz 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
8 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9 Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
10 CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666.
11 Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
31 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
32 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
33 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
34 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
35 Drugs that may have potential CYP2B6 interactions.
36 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
37 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
38 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
39 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
40 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
47 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
48 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
49 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
50 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
51 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
52 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
53 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
54 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
55 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
56 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
57 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
58 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
59 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
60 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
61 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
62 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
63 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
64 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
65 Duval X, Le Moing V, Longuet P, et al "Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir." Antimicrob Agents Chemother 44 (2000): 2593. [PMID: 11012391]
66 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
67 Cerner Multum, Inc. "Australian Product Information.".
68 Product Information. Dovato (dolutegravir-lamivudine). ViiV Healthcare, Research Triangle Park, NC.
69 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
70 Canadian Pharmacists Association.
71 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
72 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
74 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
75 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
76 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
77 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
78 Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
79 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
80 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
81 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
82 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
83 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
84 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
85 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
86 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
87 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
88 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
89 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
90 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
91 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
92 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
93 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
94 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
95 Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
96 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
97 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
98 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
99 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
100 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
101 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
102 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
103 Cerner Multum, Inc. "Canadian Product Information.".
104 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
105 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
106 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
107 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
108 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
109 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
110 Anderson GD "Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs." Neurology 63(10 Suppl 4) (2004): S3-8. [PMID: 15557548]
111 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
112 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
113 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
114 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
115 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
116 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
117 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
118 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
119 American Thoracic Society, CDC, Infectious Diseases Society of America "Treatment of tuberculosis." MMWR Morb Mortal Wkly Rep 52(RR-11) (2003): 1-77. [PMID: 12836625]
120 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
121 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
122 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
123 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
124 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
125 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
126 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
127 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
128 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
129 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
130 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
131 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
132 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
133 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
134 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
135 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
136 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
137 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
138 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
139 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
140 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
141 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
142 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
143 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
144 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
145 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
146 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
147 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
148 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
149 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
150 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
151 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
152 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
153 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
154 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
155 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
156 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
157 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
158 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
159 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
160 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
161 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
162 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
163 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
164 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
165 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
166 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
167 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
168 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
169 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
170 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
171 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
172 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
173 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
174 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
175 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
176 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
177 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
178 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
179 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
180 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
181 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
182 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
183 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
184 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.